Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

tion ratio.

"Zoticon is delighted that Sopherion Therapeutics LLC has accomplished its recruitment objectives for the Phase III registration trial in a timely and efficient manner, which can be directly attributed to the strength and quality of its management team," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board of Sopherion Therapeutics LLC.

"Myocet has the potential to be a valued addition to the treatment of metastatic breast cancer," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "We look forward to reporting the efficacy results from this clinical trial after the required period of follow-up."

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats -- its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion en
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , November 21, 2014 , ... responsable comercial   Mariano Rodríguez es elegid ... KLOX está en marcha para comenzar de ... cura de heridas de reciente aprobación en Europa   , ... compañía") se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Author ... Short Walk to the Other Side” published as ... “Award-Winning Finalist in the “Fiction: Short Story” category of ... Jeffrey Keen, President and CEO of USA Book News, ... mainstream and independent publishers, including Simon & Schuster, Penguin, ...
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) and ... PCI, Inc., leading suppliers of ozone process technology ... to provide a new state-of-the-art ozone system for ... Wastewater Treatment. The new ozone disinfection system ... dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ozone ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... University of Warwick have found that tiny nanoparticles could ... of two non mixing liquids than previously believed. ... the uses of nanoparticles in living cells, polymer composites, ... are also working on ways of further artificially enhancing ...
... NEW YORK, Feb. 17 The following is from ... article, "Ruin Your Health With the Obama Stimulus Plan."I ... issue a correction. Mr. Olbermann charges that I, Betsy ... pharmaceutical industry, the biotech industry, the Hudson Institute, or ...
... Pa., Feb. 17 Environmental Tectonics Corporation,s (Amex: ... Division today announced the sale of two (2) BARA-MED(R) ... SC, USA.ETC is delighted to work with Oasis Hyperbarics, ... MD and Tim Osbon, MD. Oasis Hyperbarics is affiliated ...
Cached Biology Technology:Nanoparticles double their chances of getting into sticky situations 2Environmental Tectonics Corporation's BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation's BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers 3Environmental Tectonics Corporation's BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers 4
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... 26 2012) Tufts University School of Engineering researchers ... that maintains the collagen,s natural strength and fiber structure, ... Collagen, the most abundant protein in the body, ... because it is biocompatible and biodegradable. Collagen is, however, ...
... cells, embryonic stem cells are by definition equipped to assume ... as an organism develops, stem cells must be ready at ... used to turn them into blood, brain, or kidney cells. ... Shilatifard, Ph.D., report in the December 27, 2012 online issue ...
... Second Life, female avatars expose substantially more skin than ... research published December 26 in the open access journal ... from Laval University, Canada. The human tendency ... cultural constraints, so measuring people,s propensity to reveal skin ...
Cached Biology News:Slice, stack, and roll: A new way to build collagen scaffolds 2Stowers study hints that stem cells prepare for maturity much earlier than anticipated 2Stowers study hints that stem cells prepare for maturity much earlier than anticipated 3
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Cytofix Buffer 100 mls...
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Biology Products: